Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
Address Details
Address: YALELAAN 62
City: UTRECHT
State: P7
Country: NLD
Zip Code: 3584
Contact Details
31-0-30-253-8800
This weeks newsletter: 🚀 Retail Access to SpaceX, BlackBerry’s Big Moves, Trends to Watch 📈